Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer

Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer

<p>Systemic treatment received by patients prior to selective FGFR inhibitors, according to the detection of FGFR kinase domain mutations and/or PI3K/mTOR pathway alterations.</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Francesco Facchinetti (16827090) (author)
Autres auteurs:	Antoine Hollebecque (15010338) (author), Floriane Braye (16827093) (author), Damien Vasseur (16827096) (author), Yoann Pradat (15352227) (author), Rastislav Bahleda (16617234) (author), Cédric Pobel (16617263) (author), Ludovic Bigot (16617254) (author), Olivier Déas (16827099) (author), Juan David Florez Arango (16827102) (author), Giorgia Guaitoli (16827105) (author), Hayato Mizuta (16827108) (author), David Combarel (16827111) (author), Lambros Tselikas (15019536) (author), Stefan Michiels (9081965) (author), Sergey I. Nikolaev (15061686) (author), Jean-Yves Scoazec (15036392) (author), Santiago Ponce-Aix (16827114) (author), Benjamin Besse (15061674) (author), Ken A. Olaussen (16827117) (author), Yohann Loriot (15123021) (author), Luc Friboulet (15025943) (author)
Publié:	2025
Sujets:	Cancer Therapeutic Research and Development Drug Resistance Clinical drug resistance Reversal of drug resistance Drug Targets Protein kinase & phosphatase drug targets Genitourinary Cancers Bladder cancer
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!